NLS Agreement

SmartCella has announced a new share issue to accelerate growth and support commercialization of the Extroducer and the company’s cell and mRNA operations. The share issue was supported by existing large institutional investors such as Fjärde AP-fonden, AMF Pension and SEB-Stiftelsen, as well as a new long-term strategic investor, AstraZeneca (committing to approximately half of […]

SciBase Holding continues to expand in California with a collaboration agreement with Unified Health. Unified Health has nine clinics in Southern California. “At Unified Health, we believe in providing our patients with exceptional medical care and access to the most advance medical technology. Our experienced team of providers are committed to delivering the highest quality […]

Elicera Therapeutics has entered a research collaboration with Fourth Affiliated Hospital of China Medical University (CMU4). Through this agreement, the efficacy of the oncolytic virus ELC-201 will be evaluated in preclinical proof-of-concept studies across multiple solid tumor indications. “We are very pleased to have been able to establish yet another scientific collaboration to advance the development […]

Elicera Therapeutics has entered a research collaboration with Fourth Affiliated Hospital of China Medical University (CMU4). Through this agreement, the efficacy of the oncolytic virus ELC-201 will be evaluated in preclinical proof-of-concept studies across multiple solid tumor indications. “We are very pleased to have been able to establish yet another scientific collaboration to advance the development […]

Data generated in the course of the collaboration have altered the risk-benefit profile within the intended indications. Merck will return all rights according to the licensing and collaboration agreement that was entered between the two parties in February 2023. Aqilion will ensure that all data and materials will be transferred to the company and will […]

The two companies have announced a strategic partnership to use Shinobi’s immune evasive iPS-T cell platform with novel candidate TCRs, discovered and validated by Anocca, to develop a new class of off-the-shelf allogeneic TCR engineered iPS-T-cell therapies (TCR-iPS-T) for solid tumors. “As we prepare to progress our first gene-edited autologous TCR-T product into the clinic, […]